『Asbestosis: Pathogenesis, Clinical Diagnosis, and Management Strategies in the Hospitalized Patient』のカバーアート

Asbestosis: Pathogenesis, Clinical Diagnosis, and Management Strategies in the Hospitalized Patient

Asbestosis: Pathogenesis, Clinical Diagnosis, and Management Strategies in the Hospitalized Patient

無料で聴く

ポッドキャストの詳細を見る

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 In this episode of Hospital Medicine Unplugged, we sprint through asbestosis—understand how inhaled fibers trigger progressive pulmonary fibrosis, recognize key radiographic features, and manage patients with attention to malignancy risk and progressive fibrotic disease. We start with pathophysiology, where the story begins decades before symptoms appear. After inhalation, asbestos fibers deposit in the distal airways and alveoli. Alveolar macrophages attempt to engulf these fibers, but many fibers are too long to be fully internalized—triggering “frustrated phagocytosis.” This leads to persistent macrophage activation and release of inflammatory mediators including TNF-α, IL-1, and TGF-β. At the same time, reactive oxygen species form both from macrophage activation and from iron on the fiber surface, amplifying oxidative injury. A key early event is alveolar epithelial cell apoptosis, driven by mitochondrial injury, p53-mediated pathways, and endoplasmic reticulum stress. Loss of epithelial integrity and chronic inflammation stimulate fibroblast activation and collagen deposition, ultimately producing the progressive interstitial fibrosis that defines asbestosis. Not all asbestos fibers carry the same risk. Amphibole fibers—particularly crocidolite and amosite—are far more fibrogenic and carcinogenic than chrysotile fibers. Their needle-like shape, durability, and resistance to biological clearance allow them to persist in lung tissue for decades. Fiber dimensions matter: long fibers (>10–20 μm) and extremely thin fibers (<0.25 μm) pose the highest disease risk because they reach distal lung regions and resist macrophage clearance. One of the defining features of asbestos disease is extraordinary latency. Clinical asbestosis usually develops 20–40 years after the first exposure, with peak disease occurrence around 40–45 years after exposure begins. Lung cancer tends to occur earlier, typically 30–35 years after exposure. Disease progression varies—some patients remain stable while others develop progressive fibrotic lung disease with significant annual declines in FVC, particularly those with fibrotic patterns on HRCT. Diagnosis relies on a combination of exposure history, latency, imaging, and pulmonary function testing. According to consensus guidelines, the diagnosis requires: • Documented asbestos exposure • Appropriate latency interval • Radiographic evidence of interstitial fibrosis • Restrictive lung disease with reduced DLCO While chest X-ray can detect classic small irregular opacities, high-resolution CT is far more sensitive. Key HRCT findings include: • Subpleural curvilinear lines (one of the most specific findings) • Intralobular and interlobular septal thickening • Parenchymal bands • Honeycombing in advanced disease Importantly, most patients with asbestosis also show benign pleural abnormalities, such as pleural plaques or diaphragmatic pleural thickening, which strongly support asbestos exposure. Unfortunately, no disease-modifying therapies are currently approved specifically for asbestosis. Management traditionally focuses on supportive care, including: • Smoking cessation • Vaccination against influenza and pneumococcus • Pulmonary rehabilitation • Oxygen therapy for hypoxemia However, the treatment landscape is evolving. Because asbestosis can behave like other progressive fibrosing interstitial lung diseases, antifibrotic therapies are increasingly considered for patients with progressive disease. Nintedanib, approved for progressive fibrosing ILD, may slow lung function decline in patients with progressive asbestosis. Early studies of pirfenidone suggest acceptable safety and potential benefit, though definitive evidence remains limited. Another critical dimension of asbestos exposure is malignancy risk. Asbestos causes two to six times more lung cancers than mesotheliomas, making asbestos-related lung cancer a major public health burden. The interaction with smoking is particularly dangerous: asbestos and smoking have a synergistic effect on lung cancer risk. In exposed workers, the combined effect can increase lung cancer mortality more than 30-fold. Importantly, asbestos exposure increases lung cancer risk even in nonsmokers, but smoking cessation dramatically reduces risk over time. Within 10 years of quitting, lung cancer mortality drops significantly, and after 30 years, risk approaches that of never-smokers. For malignant mesothelioma, amphibole fibers again carry the greatest risk. Crocidolite exposure has the highest potency, and mesothelioma risk continues to rise 40–50 years after initial exposure. Because treatment options for mesothelioma remain limited, prevention and early detection are essential. The most effective intervention is elimination of exposure, enforced through occupational safety regulations, air monitoring, and protective equipment. For individuals with significant asbestos exposure, low-dose CT ...
adbl_web_anon_alc_button_suppression_c
まだレビューはありません